Bitcoin prices plunged on Friday, and the CME briefly halted trading on the cryptocurrency’s newly-launched futures in the morning.
But one executive at the exchange says he’s “agnostic” to what the price is doing.
“Whether the talk is about the price of Bitcoin, or the enthusiasm of Bitcoin, those are all great things that make for interesting chatter and interesting topics of conversation,” Tim McCourt, Global Head of Equities and Alternative Investments at the CME, said. “But as an exchange operator we want to make sure that our customers have what they need to manage their risk, to access the process, and do so efficiently in a transparent manner. And that really isn’t necessarily a function of price, or any type of hype that’s going on in the underlying market.”
McCourt joined Cheddar the day after the world’s largest futures exchange started offering the contracts. The launch over the weekend came when Bitcoin prices were approaching $20,000. But by Friday, the digital asset was trading about 40 percent lower around $12,500.
And it wasn’t the only cryptocurrency falling. Crypto news and data resource Coindesk notes that 20 different options were down more than 20 percent over a 24-hour period on Friday. Some experts say that more exchanges getting into the sector will introduce more volatility.
For full interview [click here](https://cheddar.com/videos/cme-group-launches-bitcoin-futures-2).
Smoke that filled the cabin of a Delta flight as it took off from the Atlanta airport in February was so thick the led flight attendant had trouble seeing past the first row of passengers and the pilots donned oxygen masks as a precaution.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
